Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KCTD9P1 (Potassium channel tetramerization domain containing 9 pseudogene 1, synonym HsT38306) is classified as a pseudogene in humans. It shares sequence similarity with protein-coding members of the KCTD family, which contain an N-terminal BTB domain related to tetramerization domains in potassium channels, but unlike functional KCTD family members, KCTD9P1 does not encode a protein and does not play a role in biological signaling, disease, or therapeutic targeting. Pseudogenes like KCTD9P1 are considered "dead" genes; they result from duplication or mutation events and retain sequence similarity to functional proteins but lack expression or activity. The functional KCTD9 gene (not KCTD9P1) is an active protein with roles in cullin-dependent E3 ubiquitin ligase complexes and may be involved in cellular processes, but KCTD9P1 specifically does not produce a protein or serve as a therapeutic target. There appears to be no evidence that KCTD9P1 is a therapeutic target, biomarker, or safety risk, nor any disease associations or drug interactions in current databases or gene catalogs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium channel tetramerization domain containing 9 pseudogene 1 (KCTD9P1).